All News

Hepatitis B (Keep)

ICYMI: AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

d Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
PMR,flag

ICYMI: Secukinumab promise in PMR is real

d David Liew, FRACP

Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

Read Article
RNL25 Weschler 2

ICYMI: EGPA in 2025

d Richard Conway, MBBChBAO, PhD

Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-known cousins. Now, however, we are seeing a discordance and following GPA/MPA management will potentially lead to both over-treatment and suboptimal treatment for EGPA. In this context, the Sunday morning session at RNL 2025 on “EGPA management in 2025 and beyond” by Dr. Michael Wechsler was both timely and clinically relevant.

Read Article
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs. @RheumNow #EULAR2025 #OP0033 https://t.co/nEiTWQEqsP
Dr. John Cush RheumNow ( View Tweet)
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/bwXgrB875k
Dr. John Cush RheumNow ( View Tweet)
Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/mdePGkHU82
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Axial Involvement in Psoriatic Arthritis Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively. https://t.co/GtYn6mrWgI https://t.co/rdTJlpxWPu

Links:

Dr. John Cush RheumNow ( View Tweet)
POSTER HALL PRESENTATION: Sponsored by AbbVie Medical Affairs + Health Impact. NEW real-world study of treatment response in patients with RA on first-line TNFi. 🗓️ At 12 months, the majority of patients without initial treatment response did not achieve subsequent response. https://t.co/k9ZjZBIaXO
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/Qy9fy3GWKm
Dr. John Cush RheumNow ( View Tweet)
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/HC0skwUKQG
Dr. John Cush RheumNow ( View Tweet)
Foot and ankle #OA is often underrecognized.. 1 in 6 people over 50 have foot OA! #EULAR2025 @RheumNow https://t.co/4wGSzC8dvi
Dr. John Cush RheumNow ( View Tweet)
How to patients with rheumatic diseases consume online health information? 78% used internet for health information 50% use it atleast a month 66% found online information superior 41% used social media! 80% using it to find treatment optio ns! @rheumnow #EULAR2025 https://t.co/ZcjwPaqsjT
Dr. John Cush RheumNow ( View Tweet)
FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab approved For HLH, now for use in adults & children w/ Still's Dz complicated by Macrophage Activation Syndrome. https://t.co/3div1fktWU https://t.co/VvSkuEoki5

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/yzQVt1fLKW https://t.co/kiX6kPPQP5

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 in numbers 💫5125 abstracts submitted from 95 countries 💫177 scientific sessions 💫350 speakers from 45 nations 💫Balanced gender split of speakers & chairpersons 💫Fresh sessions format 💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoid Tapering in SLE Dr. Yuz Yusof discusses abstract POS1224 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/oI992YLvnB https://t.co/mPmMxcpMey

Links:

Dr. John Cush RheumNow ( View Tweet)
GLP 1 Receptor Agonists in axSpA Dr. David Liew reviews POS1232 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/88Ms7ce7XX https://t.co/tt3qZH1hJT

Links:

Dr. John Cush RheumNow ( View Tweet)
Rituximab - Super Responders Exist in SLE Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona. https://t.co/LkYzMtsErn https://t.co/awRhQmbhoT

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatology RoundUp: EULAR 2025 https://t.co/csWNjWyIg7 https://t.co/B6AvK1zBqX

Links:

Dr. John Cush RheumNow ( View Tweet)
PCR: Prevalence, Cost, & Risk (6.27.2025) Dr. Jack Cush reviews the news and journal reports from last week on RheumNow. https://t.co/zt0OxwQ2BO https://t.co/eFqHwROQOj

Links:

Dr. John Cush RheumNow ( View Tweet)
×